<DOC>
	<DOCNO>NCT00610636</DOCNO>
	<brief_summary>The role surgical resection subset patient resectable hepatic metastasis convert initially non-resectable liver metastasis still clearly establish . To explore oncologic result surgical versus non-surgical method treatment subset patient , design conduct present randomize prospective study begin 2002 . The present study base follow argument predominant survival benefit surgical resection previous report series : ( 1 ) The initially non-resectable liver metastasis basically disseminate disease , even though metastasis highly responsive chemotherapy become resectable ; ( 2 ) Since evaluation resectability base image study , difficult consider surgical resection `` curative '' resectable hepatic metastasis convert non-resectable one , give limitation current imaging stool high-technology ; ( 3 ) The resectable hepatic metastasis neoadjuvant chemotherapy might represent subset hepatic metastasis biologically highly responsive chemotherapy time-to-progression metastasis might fairly long response . Additionally , metastasis might also biologically responsive cytotoxic target therapy justify patient ' continuous adoption non-surgical treatment .</brief_summary>
	<brief_title>Treatment Outcomes Hepatic Metastasis After FOLFOX-4 Therapy</brief_title>
	<detailed_description>In 2000 , de Gramont et al . Giacchetti et al . report combination chemotherapy include modulate infusional 5-Fu plus irinotecan oxaliplatin could achieve response rate approximately 50 % median survival excess 20 month . These encouraging result imply chemotherapy likely play increasingly important role decrease size metastasis allow liver resection . Interestingly , Adam Bismuth et al . report 5-year overall survival 50 % ( 95 % confidence interval 33-68 % ) , observed patient resection follow neoadjuvant chemotherapy , comparable patient primarily resectable hepatic metastasis report Scheele et al . ( 39 % , 469 patient ) , Fong et al . ( 37 % , 1001 patient ) , Nordlinger et al . ( 28 % , 1568 patient ) , Fiqueras et al . ( 36 % , 235 patient ) . Recently , Zelek et al . report intravenous hepatic artery infusion irinotecan/ 5-fluorouracil/ leucovorin could facilitate complete resection initially non-resectable hepatic metastasis . Pozzo et al . indicated neoadjuvant treatment unresectable liver disease irinotecan/ 5-fluorouracil/ leucovorin enable significant portion patient undergo surgical resection . Alberts et al . show FOLFOX-4 therapy allow successful resection disease portion patient initially judge optimally resectable high recurrence rate surgery . Masi et al . report neoadjuvant approach irinotecan plus FOLFOX-4 significant antitumor activity provide radical surgical resection initially unresctable hepatic colorectal metastasis promise median survival patient . However , study publish till retrospective analysis without control group case series limit patient number and/or short time follow-up . Therefore , role surgical resection subset patient resectable hepatic metastasis convert initially non-resectable liver metastasis still clearly establish . To explore oncologic result surgical versus non-surgical method treatment subset patient , design conduct present randomize prospective study begin 2002 . The present study base follow argument predominant survival benefit surgical resection previous report series : ( 1 ) The initially non-resectable liver metastasis basically disseminate disease , even though metastasis highly responsive chemotherapy become resectable ; ( 2 ) Since evaluation resectability base image study , difficult consider surgical resection `` curative '' resectable hepatic metastasis convert non-resectable one , give limitation current imaging stool high-technology ; ( 3 ) The resectable hepatic metastasis neoadjuvant chemotherapy might represent subset hepatic metastasis biologically highly responsive chemotherapy time-to-progression metastasis might fairly long response . Additionally , metastasis might also biologically responsive cytotoxic target therapy justify patient ' continuous adoption non-surgical treatment .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>1 . Secondary resectable hepatic metastasis convert FOLFOX4 regimen . 2. age 1880 y/o . 3. extrahepatic disease 4. life expectancy ≥ 3 month 5 . Karnofsky performance status ≥ 50 % . 6 . WBC count ≥ 4,000/μl , platelet count ≥ 100,000/μl , serum bilirubin ≤ 2.0 mg/dl normal serum glucose electrolyte level . 1 . Secondary resectable hepatic metastasis extrahepatic disease 2. poor liver function include : serum bilirubin &gt; 2.0 mg/dl , GOT , GPT &gt; 100 U/L 3. severe steatosis hepatitis sinusoidal dilation 4 . Karnoofsky performance status &lt; 50 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>FOLFOX-4</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>resectability</keyword>
</DOC>